ATLANTA -- Supplies of human rabies biologicals for pre- or postexposure prophylaxis in the United States are "manageable, but are expected to be less than ideal" over the next few years, Charles E. Rupprecht, V.M.D., said at the winter meeting of the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention.
The CDC, along with the Food and Drug Administration and industry, "continue to work together towards productive solutions to this problem," said Dr. Rupprecht, chief of the CDC's rabies program.
Since the winter meeting, ACIP has formed an ad hoc working group to address the problem.
The group is currently discussing ...